Preetesh Jain, MD
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Preetesh Jain, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07257055 · Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 StudyM.D. Anderson Cancer Center · recruiting · Phase 2 Study, MCL, BTKi · principal investigator
- Ph2NCT05529069 · Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsM.D. Anderson Cancer Center · recruiting · Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy · principal investigator
- Early Ph1NCT05495464 · A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell LymphomaM.D. Anderson Cancer Center · active not recruiting · Lymphoma, Mantle Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.